AcuraStem is a fast growing startup company that was formed in 2016 to create an innovative precision medicine platform. We are a team of PhDs, professors, tech entrepreneurs, and successful drug company veterans employing the latest scientific breakthroughs to address one of the most challenging, but we believe tractable, health problems of our time — Amyotrophic Lateral Sclerosis (ALS). We are developing the best-in-class technology platform which consists of complex cellular models from ALS patient cells, and sophisticated assays which permit our scientists to model patient tissues in the laboratory. Using this advanced technology, we can evaluate the progression of disease and test existing FDA approved therapeutics or combinations of therapeutic approaches to find the most efficacious treatments to slow disease progression. AcuraStem has leveraged this platform to identify a novel target and preclinical lead candidate which we are advancing to the clinic. AcuraStem also provides access to this technology platform to commercial and academic partners so that they can evaluate their therapeutic candidates under development.
apceth Biopharma is a pioneering clinical stage biopharmaceutical company and a successful contract development & manufacturing organization (CDMO) for complex cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs) located in Munich, Germany.
The company was founded in 2007 as apceth GmbH & Co. KG. It is owned by the investors and the scientific founders.
We are at the forefront of the discovery, development and commercialization of novel Alzheimer’s disease therapeutics that will fundamentally improve patient outcomes, quality of life, and disease management. Preventing Alzheimer’s disease progression remains a critical, unmet need for millions of people in the US and worldwide. Our advanced knowledge of Alzheimer’s disease biology, combined with our proprietary scientific discoveries, and clinical and biomarker imaging expertise, provides AZTherapies with unique potential to develop novel therapies to impact Alzheimer’s disease progression.
Biosceptre is a UK headquartered biotech developing next-generation cancer therapeutics utilising its proprietary target, nfP2X7. Biosceptre has an experienced team of scientists and executives based in state of the art facilities at the Babraham Research Campus, Cambridge UK and at Sydney Australia. Biosceptre has multiple clinical programs designed to exploit nfP2X7 via a range of modalities including systemic antibodies, vaccines and topical therapeutics. A’s comprehensive global IP portfolio covers broadly both the target itself and multiple drug modalities, as well as multiple candidates designed to exploit nfP2X7.
Cantex's pipeline has two product candidates in Phase II clinical development:
CX-01, a polysaccharide that is a new chemical entity, neutralizes the activity of proteins that play a role in the adhesion of leukemia stem cells to the protective bone marrow environment, and neutralizes the activity of platelet factor 4, a cytokine which suppresses and delays platelet recovery after chemotherapy. CX-01 is in Phase II clinical trials for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) Dicopp™ (formerly known as CX-02), a proprietary combination of disulfiram + copper, is in a Phase II clinical trial for recurrent glioblastoma and in a separate investigator-initiated clinical trial for metastatic castration-resistant prostate cancer, with plans to enter Phase II clinical trials for metastatic pancreatic cancer and metastatic non-small cell lung cancer in 2018, pending financing.
Cue Biopharma is committed to bringing selective immune modulation to patients through our Cue Biologics platform. Our talented scientists are led by an experienced management team and supported by leading scientific and clinical advisors with deep expertise in the design and clinical development of protein biologics to treat cancer and autoimmune diseases. Together, we are developing novel, targeted therapies aimed at overcoming many of the challenges facing prevailing immunotherapeutics. We are headquartered in Kendall Square, Cambridge, MA.
Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.
The Company’s lead therapeutic program, eltoprazine is a small molecule indicated for the treatment of Levodopa-induced dyskinesia, one of the most difficult problems facing patients with Parkinson’s disease. Eltoprazine is currently in a Phase 2b clinical trial with results from the study expected in 2016. Eltoprazine is also being evaluated for the treatment of adult attention deficit hyperactivity disorder (ADHD) and Alzheimer’s aggression.
Emerald Health Pharmaceuticals (EHP) is a private drug development company focused on patented non-psychotropic cannabinoid analogues for the treatment of inflammatory, auto-immune, neurodegenerative, fibrotic, and metabolic diseases. The Company's portfolio of over twenty patented molecules are chemically-modified derivatives of cannabidiol (CBD) and cannabigerol (CBG), specifically designed to improve the therapeutic properties of these natural compounds by addressing multiple biological targets and physiologic pathways that have been demonstrated to play key roles in specific central nervous system (CNS), auto-immune, inflammatory, metabolic, and fibrotic diseases. The first two selected product candidates from this portfolio of molecules (EHP-101, a CBD analogue, and EHP-102, a CBG analogue) are being developed to address unmet medical needs in the treatment of multiple sclerosis, scleroderma, Huntington's Disease and Parkinson’s Disease. EHP expects to begin human trials on EHP-101 in 2018 and on EHP-102 in 2019.
Hemispherx Biopharma, Inc. - [NYSEAMERICAN: HEB]
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.
Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutics Ampligen®. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because Ampligen® is experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials.
The FDA approval of Alferon N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company’s Alferon® N approval in Argentina includes the use of Alferon N Injection® (under the brand name “Naturaferon”) for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection.
The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream that enhances penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement of Arginine sexual and cognitive functions; and Androferti, a natural supplement to support overall male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, Ketones, krill oil, Omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; and UriVarx, a proprietary supplement for overactive bladder and urinary incontinence. The company’s pipeline products include FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; Xyralid, a lidocaine based cream for the relief of pain and symptoms caused by hemorrhoids; AllerVarx, a patented formulation produced in bilayer tablets; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
LB is focused on the multi-billion dollar US antipsychotic market and is developing a proprietary, patented version of amisulpride. Amisulpride is a successful anti-psychotic drug approved in Europe with millions of prescriptions filled throughout Europe/CIS/PacRim yearly comprising a market share within schizophrenia of 5-10% (depending on the country). Well-controlled trials stretching back twenty years have documented amisulpride’s effective treatment of the negative symptoms of schizophrenia as well as depressive disorders. More specifically, the data shows that amisulpride is one of the most effective antipsychotics in the world with no statistically significant difference in efficacy between amisulpride and the two drugs that currently comprise 40% of the US market (olanzapine and risperidone).
LB Pharma has changed the chemical structure of amisulpride to create a novel asset that could improve its efficacy and/or improve safety. In pre-clinical testing to date, results show that LB-102 and LB-103 (-102 is our racemic version and -103 is a single enantiomer version of the same molecule):
1) Have a CNS receptor binding profile that matches amisulpride, specifically slightly higher affinity at D2/D3 receptors 2) Have an oral pharmacokinetic profile in mice and rats that matches amisulpride 3) Have better membrane permeability than amisulpride 4) Are as efficacious or more efficacious than amisulpride in rat models of schizophrenia 5) Has a 14-day toxicity profile in rats that matches amisulpride (MTD of 200 mg/kg/day)
If approved by the FDA, LB-102 and/or -103 would be the first benzamide atypical approved for the US market.
MaxCyte is a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte’s team of scientific experts helps its partners unlock the potential of their products and solve development and commercialization challenges. MaxCyte is developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture chimeric antigen receptor (CAR) therapies for a broad range of cancer indications, including solid tumors where existing chimeric antigen receptor T cell (CAR-T) approaches face significant challenges. https://www.maxcyte.com/
NEMUS Bioscience, Inc. - [OTCMKTS: NMUS]
NEMUS Bioscience Inc. is a life-science, biopharmaceutical company focused on discovering, developing and commercializing cannabinoid-based therapeutics. These molecules display multi-functional activity by virtue of selectively binding to two types of cannabinoid receptors (CB1 and CB2 receptors) located throughout multiple organ systems in the body. NEMUS is developing novel and proprietary classes of product candidates that have a global patent footprint with a goal of enhanced chemical engineering, leading to more predictable bioavailability and pharmacokinetics resulting in optimized efficacy and safety.
The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.
The technology platform developed by Okairos is based on recombinant primates’ Adenovirus and Modified Vaccinia Virus Ankara (MVA) expressing antigens from infectious agents. Application of this technology led to novel vaccines targeting HCV, Malaria, RSV and Ebola among others. These products have been evaluated in more than 4,000 subjects of all ages including adults, newborns and elderly healthy volunteers, as well as patients suffering from chronic infectious diseases.
Building on previous experience and successes, NousCom has developed novel viral vectors, similar to the ones tested in the clinic against infectious diseases, encoding neoantigens for the treatment of cancer. Tumor neoantigens are believed to be potent immunogens with low risk of inducing autoimmunity that are detected by the immune system as “non-self” antigens, very similar to exogenous pathogens.
ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the TSX (ticker symbol: PMN.TO). As a development stage biotech company ProMIS’ mission is the discovery and development of best in class precision therapeutics for treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).
STALICLA has developed an algorithm which organizes and cross-links ASD focused research data with non-autism specific research data. The generated output is filtered with non-behavioral sets of clinical signs and symptoms. Therapeutic target hypotheses are then generated in a probabilistic manner. By combining therapeutic targets hypotheses with publicly available drug repurposing programs and strategies, STALICLA identifies specific biomarkers, therapeutic targets, and susceptibility gene pools. STALICLA’s algorithm is dynamic and constantly enriched.
TapImmune is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. The company’s next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i.e. checkpoint inhibitors). The company’s off-the-shelf vaccines boost patients’ immune systems to comprehensively stimulate both killer T-cells and helper T-cells to destroy cancer cells, and they are designed to work with 80% of the population. TapImmune is advancing two clinical stage T-cell vaccine candidates in multiple Phase II and Phase Ib/IIa clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from FDA Fast Track and Orphan Disease Designation. The company is working in collaboration with industry and clinical leaders including Mayo Clinic, Memorial Sloan Kettering Cancer Center, and AstraZeneca.
Tilray is a global leader in medical cannabis research and production dedicated to providing safe, consistent and reliable therapy to patients. We are the first GMP-certified medical cannabis producer to supply cannabis flower and extract products to thousands of patients, physicians, pharmacies, hospitals, governments and researchers on four continents.
In 2013, we developed a proprietary enzymatic biosynthesis production system in order to improve the taste of stevia, a natural compound used as a high-potency sweetener. This platform harnesses a naturally-occurring biological process known as glycosylation, which involves using enzymes to attach glucose (sugars) to small-molecule compounds. Over the last 10 years or so, it has become well appreciated within the pharmaceutical industry that glycosylation can act to generate new natural product libraries with improved drug properties. This platform technology enables us to readily modify existing drug compounds, especially natural products, in order to give them attractive new drug properties.
Using our proprietary glycosylation platform, we’ve now been able to produce and characterize more than 20 novel cannabinoid glycosides, or “cannabosides”, which are novel drug candidates that represent a new class of cannabinoid pharmaceuticals. It is well established that cannabis can provide relief of pain and inflammation in certain disease indications, and our prodrugs could exert the same beneficial therapeutic effects, but with notable improvements, such as targeted drug delivery that avoids or reduces psychoactivity. Targeted delivery through glycosylation may enable selective delivery of compounds to the brain or gut, markedly improving the side effect profile or bioavailability of existing drugs.
Vitality has filed intellectual property applications and is seeking worldwide patent protection through 2035 with strong composition of matter claims for prodrugs of THC, CBD, and CBDV, as well as for its proprietary prodrug biosynthesis platform utilizing enzymatic glycosylation.
VLP Therapeutics, LLC (VLP) was established in 2012 by seasoned biopharmaceutical veterans with mission to develop innovative medical treatment which transforms traditional vaccine and targeted antibody therapies to address global unmet medical needs. Its vision is to combat the 21st century global public health problems through revolutionary next generation i-αVLP (inserted alpha VLP) Technology. The company is headquartered in Gaithersburg, Maryland.